Immunogenicity and Safety Study of a Third Vaccination With FSME-IMMUN 0.5 mL in Subjects Previously Vaccinated According to a Rapid Immunization Schedule (Follow-up to Study 225)

Phase 4

Completed

• Conditions: Encephalitis, Tick-borne

• Registration Number: NCT00163540
• Lead Sponsor: Pfizer

Brief Summary

The objective of this study is to investigate the immunogenicity and safety of a third vaccination with FSME-IMMUN 0.5 ml given approximately 12 months after the second vaccination in Study 225. In Study 225, two vaccinations were given using a rapid immunization schedule 12 ± 2 days apart.

Detailed Description

Not available

Study Timeline

• Study Start: 2005-05
• Study Completion: 2005-06
• Study First Submitted: 2005-09-08
• Study First Submitted QC: 2005-09-13
• Study First Posted: 2005-09-14
• Status Verified: 2015-05
• Last Update Submitted: 2015-05-20
• Last Update Posted: 2015-05-21

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Male and female subjects who:
• received 2 vaccinations with FSME-IMMUN 0.5 ml during Study 225
• understand the nature of the study, agree to its provisions and provide written informed consent
• are clinically healthy (i.e. the physician would have no reservation vaccinating with FSME-IMMUN 0.5 ml outside the scope of the clinical trial)
• have a negative pregnancy test result at the first medical examination (if female and capable of bearing children)
• agree to employ adequate birth control measures for the duration of the study (if female and capable of bearing children)
• agree to keep a Subject Diary

Exclusion Criteria

Subjects who:

• have already been administered a third TBE vaccination elsewhere since receiving two vaccinations in Study 225
• have a history of infection with, or vaccination against, other flaviviruses since participation in Study 225 (e.g. yellow fever, dengue fever, japanese B encephalitis)
• have had an allergic reaction to one of the components of the vaccine since participation in Study 225
• suffer from a disease (e.g. autoimmune disease, immunodeficiency) or are undergoing a form of treatment (e.g., systemic corticosteroids) that can be expected to influence immunological functions
• have a known or suspected problem with drug or alcohol abuse (>4 liters wine/week or equivalent doses of other alcoholic beverages)
• have donated blood or plasma within 30 days of study entry
• have received a blood transfusion or immunoglobulins within 30 days of study entry
• are known to be HIV positive (an HIV test is not required specifically for this study)
• are simultaneously participating in another clinical trial including administration of an investigational product
• have participated in any other clinical study within 6 weeks prior to study start
• have participated in another Baxter vaccine study in the past 6 months (with the exception of follow-up studies)
• For female subjects: pregnancy or lactation

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Trial Locations

Locations (1)

SGS Biopharma Research Unit Stuivenberg; 🇧🇪 Antwerp, Belgium